Analysts/Institutional Investor Meet/Con. Call Updates

FISCHER MEDICAL VENTURES LIMITED Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548 September 7, 2026 To To BSE Limited National Stock Exchange of India Ltd. Exchange Corporate Relationship Department Plaza, 5tll floor 25th Floor, P J Towers Plot No. C/ 1, G Block, Dalal Street, Fort, Bandra-Kurla Complex Bandra (E), Mumbai – 400 001 Mumbai - 400 051 BSE Scrip Code: 524743 NSE Symbol: FISCHER Dear Sir/ Madam, Sub: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to our letter dated September 4, 2026 and in terms of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please see enclosed copy of the presentation for the Investor/Analyst call scheduled to be held September 7, 2026(today). This is for the information of the exchange and the members. Thanking you, Yours Truly, For FISCHER MEDICAL VENTURES LIMITED BALAJI GANDLA COMPANY SECRETARY AND COMPLIANCE OFFICER Corporate Office: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006 INVESTOR& STRATEGPIACR TNERSHIPPR ESENTATION Fischer Medical Ventures Limited FiscMheedriV ceanlt Luirmeist ed Builtdhiweno gr llda'rsg est HealtAhlSc oalruePt liaotfonrsm Al-enMaebdlieIcdma alg IiPn ogp ulatiSocnr-eseIcnHai olnsegp Diitgailt ization June 2026 Confnitldi DeaoI Not Distribute CORPORATES TRUCTURE FMVG roOurpg anization Integhreaatletdih ncnaorveea ctoisoynas ctredomis asg nosbtiioclsao,ng idiAn clts,e rnvaetnitounraels TimeM edical MrR.a vi Govindan MercCaatpuist al Mr. ShankarV. HoldCionL.gt sd (Promoter) PtLet d (Promoter) MEDICATLE CHNOLOGY AlH EALTHCARE INTERNATIONAL & DIAGNOSTICS & DIGTIAL HEALTH VENTURES •TimMee diIcanlt ernVaetnitounrLaedtls( 1P0v0t% ) •FlynnCaHreea Ilntnho vPatviLtont s(d 1 00%) FiscHhoesrp iStDaBNlH iD(t 6y0 %) •Blusim Technologies Pte Ltd (20%)• PellucHiedaIclnatnrhoe va PttiLeot n(ds1 00%) •FMV InternaVteinotnuarLlet s(d 1 P0t0e% ) •SASCANM editPvetLc th(d 1 9.9%) •Nanyang (BIinoPvdltiLog ati)(dc 5 s1 %) •FMV TechnoSlDoBNgH iD(e 1s00 %) •Therapy PLlta(dt2 f0o%r)m Pte •WonderTecSho lHuetPvaitlo tnL(hst5 d1 %) •NanMoe dTiecc hno&l oSgoileu{st1 io5n%s) •FMV GloIbanln ovaPttLieto {dn1 s00 %) KE v TAKE AFwM hVAa vb su ainli tn teghreaatletidhn cnaorveeac toisoysnsp taenAmnd liai gnngo smteidcitsce,ac lh nodliiogtghaielea sl,tp hlcaatrfbeoi romlso,g ics anidn ternvaetnitaoucnrraeAolsss isa . June 2026 ConfidIeD not iNDaoilts tribute DIRECTORS FMV List of Directors Board of Directors Whole Time Director Chairman & Managing Director Independent Director Svetlana Rao Raviwada Ravindran Govindan Khairy Jamaluddin Abu Bakar • Electronics & Communications Engineer with prior • Former Chairman & President (APAC), Fisher Scientific • Former Minister of Health, Malaysia roles at Wipro & Alcatel R&D Inc. • Led national COVID-19 response and digital healthcare • Led establishment of FMV India operations • 45+ years across healthcare, investments & technology initiatives • Oversees India business strategy and operations • Early investor and strategic advisor to Time Medical • Brings Southeast Asian healthcare policy and Group governance expertise June 2026 Confidential | Do Not Distribute DIRECTORS FMV List of Directors Board of Directors Independent Director Independent Director Independent Director Ms. Jaya Ankur Singhania Mr. Richard Chan Sing En Dr. Syed Jalaluddin • 15+ years in corporate governance and legal advisory • 30+ years in private equity and corporate finance • Distinguished academic, scientist & corporate leader • Expertise in compliance, CSR, IP rights & board • Extensive experience across Southeast Asia & Australia • Contributor to Malaysia's halal ecosystem and Islamic governance • Provides strategic financial and investment advisory banking sector • Supports regulatory oversight and governance insights • Brings deep technical, scientific and governance frameworks expertise June 2026 Confidential | Do Not Distribute